Glenmark to launch Leucovorin Calcium for Injection in US

Glenmark Pharmaceuticals Inc., USA, announced its upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. This new product is bioequivalent and therapeutically equivalent to the reference listed drug from Hospira, Inc. Distribution is scheduled to commence in December 2025.

The market for Leucovorin Calcium for Injection, 350 mg/vial, recorded annual sales of approximately $16.8 million for the 12-month period ending October 2025, according to IQVIA® sales data. Marc Kikuchi, president & business head, North America, stated that this launch further expands Glenmark's institutional channel portfolio and reinforces its commitment to providing quality and affordable alternatives for patients.

Glenmark Pharmaceuticals, a global pharmaceutical company with a presence across branded, generics, and OTC segments, focuses on respiratory, dermatology, and oncology. The company operates 11 manufacturing facilities across four continents and in over 80 countries.